Chlorogenic acid is a major phenolic compound in Lonicera japonica Thunb. It is an orally active antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, anti-microbial, anti-hypertension compound[1][2][3].
Chlorogenic acid (10 μM, 16 h) 可降低 CoCl2 诱导的缺氧 A549 细胞中的 HIF-1α 蛋白水平,但不影响 HIF-1α mRNA 水平[1]。
Chlorogenic acid (10 μM,24 h) 抑制缺氧诱导的 HUVEC 细胞迁移、侵袭和血管内皮细胞管形成[1]。
Chlorogenic acid (25, 50 μM, 24 h) 抑制 Huh7 细胞增殖,并减少入侵和迁移细胞的数量[4]。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Chlorogenic acid (10 μM, 皮下注射) 通过抑制 AKT 激活来抑制 C57BL/6J 小鼠中 VEGF (200 ng/mL) 诱导的血管生成 (基质胶塞测定)[1]。
Chlorogenic acid (10-100 mg/kg,口服) 对大鼠实验性反流性食管炎具有保护作用[3]。
Chlorogenic acid (10 mg/kg,静脉注射) 可预防 LPS 中毒的 C57BL/6 小鼠的内毒素死亡和诱导的 TNF-α 释放,并改善 LPS/GalN 攻击小鼠的急性肝损伤[2] .
Chlorogenic acid (腹腔注射,25-200 mg/kg) 可抑制接种 Huh7 或 H446 细胞的 NOD/SCID 小鼠的肿瘤生长[4]。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Experimental reflux esophagitis (RE) in rats[1] |
Dosage: | 10, 30, 100 mg/kg |
Administration: | p.o. |
Result: | Reduced esophageal lipid peroxidation (marker: MDA) and increased the reduced glutathione/oxidized glutathione ratio. Inhibited the increases in the serum level of TNF-α, and expressions of iNOS and COX-2 protein. |
Animal Model: | LPS/GalN-challenged mice[2] |
Dosage: | 10 mg/kg |
Administration: | i.v. |
Result: | Increased survival rates of LPS/GalN-intoxicated mice. Inhibited LPS/GalN-induced phosphorylation of NF-κB p65 or c-Jun, without affecting p-IRF3 levels in the liver lobules. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03751592 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd|Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Advanced Lung Cancer | July 17, 2018 | Phase 1|Phase 2 |
NCT02728349 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd|Beijing Shijitan Hospital, Capital Medical University | Glioblastoma | April 12, 2016 | Phase 1 |
NCT02388672 | University Hospital Tuebingen | Blood Pressure | March 2015 | Not Applicable |
NCT03758014 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | GBM | November 27, 2018 | Phase 2|Phase 3 |
NCT02621060 | University of Guadalajara | Impaired Glucose Tolerance | September 2015 | Phase 2 |
NCT02136342 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | Advanced Cancer | May 2014 | Phase 1 |
NCT02245204 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd|Peking University Cancer Hospital & Institute | Advanced Cancer | September 2014 | Phase 1 |
NCT03444558 | University of Palermo|University of Catania | Metabolic Syndrome | June 1, 2017 | Not Applicable |
NCT02929901 | National Nutrition and Food Technology Institute | Type 2 Diabetes Nonalcoholic Fatty Liver | December 2016 | Phase 2|Phase 3 |
NCT02524938 | NHS Greater Glasgow and Clyde|University of Glasgow | Diabetes Mellitus, Type 2|Renal Insufficiency, Chronic | June 1, 2016 | Not Applicable |
354.31
C16H18O9
固体
White to off-white
绿原酸;3-咖啡酰奎尼酸;咖啡单宁酸;咖啡酰奎尼酸;氯吉酸;绿源酸
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 1 year |
-20°C | 6 months |
DMSO 中的溶解度 : 100 mg/mL (282.24 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)
H2O 中的溶解度 : ≥ 20 mg/mL (56.45 mM)
* '≥' means soluble, but saturation unknown.
浓度 溶剂体积 质量 | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.8224 mL | 14.1119 mL | 28.2239 mL |
5 mM | 0.5645 mL | 2.8224 mL | 5.6448 mL |
10 mM | 0.2822 mL | 1.4112 mL | 2.8224 mL |
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。
* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
请根据您的 实验动物和给药方式 选择适当的溶解方案。
以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
联系客服